# EDGAR Filing Document

**Accession Number:** 0001658247
**File Stem:** 0001628280-26-039784
**Filing Date:** 2026-6
**Character Count:** 8754
**Document Hash:** f20c253aa1a4927d00eca03fba1321ee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-039784.hdr.sgml**: 20260602

**ACCESSION NUMBER**: 0001628280-26-039784

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260529

**FILED AS OF DATE**: 20260602

**DATE AS OF CHANGE**: 20260602

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Struthers Richard Scott
- **CENTRAL INDEX KEY:** 0001746298

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38583
- **FILM NUMBER:** 261055836

**MAIL ADDRESS:**
- **STREET 1:** C/O CRINETICS PHARMACEUTICALS, INC.
- **STREET 2:** 6055 LUSK BOULEVARD
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Crinetics Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001658247
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 263744114
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6055 LUSK BLVD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-450-6464

**MAIL ADDRESS:**
- **STREET 1:** 6055 LUSK BLVD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Struthers Richard Scott<br><sub>(Last) (First) (Middle)</sub><br>C/O CRINETICS PHARMACEUTICALS, INC.<br>6055 LUSK BOULEVARD<br><sub>(Street)</sub><br>SAN DIEGO, CA 92121<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-29 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President & CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Crinetics Pharmaceuticals, Inc. [ CRNX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-29 |  | G<sup>(1)</sup> |  | 222200 | D | $0 | 439005 | I | By Family Trust 1 |
| Common Stock | 2026-05-29 |  | G<sup>(1)</sup> |  | 222200 | D | $0 | 216805 | I | By Family Trust 1 |
| Common Stock | 2026-05-29 |  | G<sup>(1)</sup> |  | 80000 | D | $0 | 136805 | I | By Family Trust 1 |
| Common Stock | 2026-05-29 |  | G<sup>(1)</sup> |  | 222200 | A | $0 | 626978 | D |  |
| Common Stock | 2026-05-29 |  | G<sup>(1)</sup> |  | 222200 | A | $0 | 223200 | I | By Spouse |
| Common Stock | 2026-05-29 |  | G<sup>(1)</sup> |  | 80000 | A | $0 | 80000 | I | By Charitable Trust |
| Common Stock | 2026-05-29 |  | G<sup>(2)</sup> |  | 111100 | D | $0 | 515878 | D |  |
| Common Stock | 2026-05-29 |  | G<sup>(2)</sup> |  | 111100 | D | $0 | 404778 | D |  |
| Common Stock | 2026-05-29 |  | G<sup>(2)</sup> |  | 111100 | A | $0 | 111100 | I | By Family Trust 5 |
| Common Stock | 2026-05-29 |  | G<sup>(2)</sup> |  | 111100 | A | $0 | 111100 | I | By Family Trust 6 |
| Common Stock | 2026-05-29 |  | G<sup>(3)</sup> |  | 111100 | D | $0 | 112100 | I | By Spouse |
| Common Stock | 2026-05-29 |  | G<sup>(3)</sup> |  | 111100 | D | $0 | 1000 | I | By Spouse |
| Common Stock | 2026-05-29 |  | G<sup>(3)</sup> |  | 111100 | A | $0 | 111100 | I | By Family Trust 7 |
| Common Stock | 2026-05-29 |  | G<sup>(3)</sup> |  | 111100 | A | $0 | 111100 | I | By Family Trust 8 |
| Common Stock |  |  |  |  |  |  |  | 106000 | I | By Family Trust 2 |
| Common Stock |  |  |  |  |  |  |  | 110000 | I | By Family Trust 3 |
| Common Stock |  |  |  |  |  |  |  | 100000 | I | By Family Trust 4 |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) (1)	Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein.

(2) (2)	Represents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust ("Family Trust 5") and (b) the JSS Dynasty Trust ("Family Trust 6"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein.

(3) (3)	Represents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust ("Family Trust 7") and (b) the RSS Dynasty Trust ("Family Trust 8"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries.  The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein.

**Signature:** /s/ Tobin Schilke, as attorney-in-fact  
**Date:** 2026-06-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**